Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
DOTI-Me
- Development stage
- Preclinical
- Lead developer
- Saarland University
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous
01
Overview
DOTI-Me (1,4,7,10-tetrakis((1-methyl-1H-imidazol-2-yl)methyl)-1,4,7,10-tetraazacyclododecane) is a cyclen-based chelator featuring four methylimidazole arms, developed by researchers at Saarland University. It is designed for the stable complexation of various clinically relevant radiometals, including manganese-52g, copper-64, indium-111, terbium-161, bismuth-213, and lutetium-177. DOTI-Me exhibits rapid radiolabeling kinetics and high in vitro stability, making it a promising platform for the development of diagnostic and therapeutic radiopharmaceuticals (theranostics) in nuclear medicine.
- Other names
- 1,4,7,10-tetrakis((1-methyl-1H-imidazol-2-yl)methyl)-1,4,7,10-tetraazacyclododecane
Beyond the preview
Go deeper on DOTI-Me.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on DOTI-Me.